High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
Open Access
- 21 December 2021
- journal article
- research article
- Published by Elsevier in Cell Reports
- Vol. 38 (2) , 110237
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Institutes of Health (AI120898, AI122390, DA046100, R01AI158617, U19AI082630, UM1AI148574)
- Eli Lilly and Company
- Pfizer
- Merck
This publication has 20 references indexed in Scilit:
- Structural impact on SARS-CoV-2 spike protein by D614G substitutionScience, 2021
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine seraCell, 2021
- Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7Nature, 2021
- The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2Proceedings of the National Academy of Sciences, 2021
- An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2Cell Reports, 2020
- SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivityNature Communications, 2020
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacyScience, 2020
- Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 BindingCell, 2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020